Hillsdale Investment Management Inc. Takes $3.34 Million Position in Tempus AI, Inc. $TEM

Hillsdale Investment Management Inc. bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 41,400 shares of the company’s stock, valued at approximately $3,341,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Capital LLC grew its position in shares of Tempus AI by 26.9% during the 3rd quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after buying an additional 17,866 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Tempus AI by 1,459.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock valued at $8,174,000 after acquiring an additional 94,783 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new stake in Tempus AI during the 3rd quarter worth $1,695,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in shares of Tempus AI by 66.8% during the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 190,828 shares of the company’s stock valued at $15,402,000 after acquiring an additional 76,455 shares during the last quarter. Finally, Pier 88 Investment Partners LLC acquired a new position in shares of Tempus AI in the 2nd quarter valued at $286,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Robert W. Baird began coverage on Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tempus AI in a report on Thursday, January 22nd. BTIG Research upped their price target on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 25th. Piper Sandler cut their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Finally, Needham & Company LLC boosted their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $85.92.

Key Stories Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Insider Activity

In related news, CAO Ryan M. Bartolucci sold 2,902 shares of the firm’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $171,363.10. Following the sale, the chief accounting officer directly owned 41,159 shares in the company, valued at $2,430,438.95. This trade represents a 6.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Ryan Fukushima sold 9,592 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares in the company, valued at $41,001,603.70. This represents a 1.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 596,035 shares of company stock worth $37,505,125. Corporate insiders own 26.27% of the company’s stock.

Tempus AI Trading Down 2.7%

NASDAQ TEM opened at $58.37 on Monday. Tempus AI, Inc. has a one year low of $36.22 and a one year high of $104.32. The company has a debt-to-equity ratio of 2.45, a current ratio of 3.28 and a quick ratio of 3.12. The firm has a market cap of $10.38 billion, a P/E ratio of -49.05 and a beta of 5.22. The stock’s 50-day moving average is $62.35 and its 200-day moving average is $73.62.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.